Version 2.77

Part Descriptions

LP14704-8   Fibrinogen
Fibrinogen is a plasma glycoprotein that was first isolated from horse plasma in 1876. Fibrinogen is produced in the liver and constitutes 5% of the total plasma protein. It is vital to wound healing, fibrinolysis, inflammation, cellular and matrix interactions and neoplasia by interacting with numerous proteins and cells. Fibrinogen activates a series of clotting factors in response to an injury or other stimuli that leads to the enzymatic conversion of soluble fibrinogen into fibrin. Fibrin is the insoluble, structural component of blood clots. Fibrinogen is an acute phase reactant that can increase 200-400% in response to infection, chronic inflammation, smoking and other environmental stresses. [sciencedirect.com/topics/neuroscience/fibrinogen][https://www.ebi.ac.uk/interpro/potm/2006_11/Page1.htm] Source: Regenstrief LOINC

LP38153-0   Fibrinogen Ag
Fibrinogen Ag aids in the diagnosis of fibrinogen deficiencies. This assay provides information useful in the diagnosis of acquired or congenital deficiencies. It is also used for monitoring the severity and treatment of DIC and fibrinolysis. Source: Regenstrief Institute

Fully-Specified Name

Component
Fibrinogen Ag
Property
PrThr
Time
Pt
System
Tiss
Scale
Ord
Method
IF

Additional Names

Short Name
Fibrinogen Ag Tiss Ql IF
Display Name
Fibrinogen Ag IF Ql (Tiss)
Consumer Name Alpha Get Info
Fibrinogen antigen, Tissue

Example Answer List: LL1937-3

Source: 3M Health Information Systems
Answer Code Score Answer ID
PresentCopyright http://snomed.info/sct ID:52101004 Present (qualifier value) LA9633-4
AbsentCopyright http://snomed.info/sct ID:2667000 Absent (qualifier value) LA9634-2

Basic Attributes

Class
COAG
Type
Laboratory
First Released
Version 2.34
Last Updated
Version 2.73
Change Reason
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.
Order vs. Observation
Both
Common Test Rank Get Info
12618

Language Variants Get Info

Tag Language Translation
es-ES Spanish (Spain) Fibrinógeno Antígeno:PrThr:Punto temporal:Tejido:Ord:Inmunofluorescencia (IF)
es-MX Spanish (Mexico) Fibrinógeno Ag:Presencia o umbral:Punto temporal:Tejido y frotis:Ordinal:Inmunofluorescencia (IF)
et-EE Estonian (Estonia) Fibrinogeen antigeen:PrThr:Pt:Tis:Ord:IF
Synonyms: Järgarvuline Juhuslik Kude
fr-CA French (Canada) Fibrinogène , Ag:Présence-Seuil:Temps ponctuel:Tissu:Ordinal:Immunofluorescence
fr-FR French (France) Fibrinogène antigène:Présence/Seuil:Ponctuel:Tissu:Qualitatif:Immunofluorescence
fr-BE French (Belgium) Fibrinogène Ag:PrThr:Temps ponctuel:Tissu:Ordinal:Immunofluorescence
Synonyms: Antigène
it-IT Italian (Italy) Fibrinogeno , Ag:PrThr:Pt:Tessuto:Ord:IF
Synonyms: Immunofluorescenza (IF) Presenza o Soglia Punto nel tempo (episodio) Studio di coagulazione Tessuto & Strisci
nl-NL Dutch (Netherlands) fibrinogeen Ag:aanwezigheid:moment:weefsel en uitstrijkjes:ordinaal:immunofluorescentie
Synonyms: antigeen coagulatiemethode IF
pt-BR Portuguese (Brazil) Fibrinogênio Ag::Pt:Tecido:Ord:Imunofluorescência
ru-RU Russian (Russian Federation) Фибриноген Аг:PrThr:ТчкВрм:Тк:Пор:ИФ
Synonyms: Иммунофлюоресценция (ИФ) Порядковый Ткань и мазки Точка во времени;Момент
tr-TR Turkish (Turkey) Fibrinojen Ag:MevcEşik:Zmlı:Doku:Srl:IF
Synonyms: Antijen İmmünflorerans Mevcut
zh-CN Chinese (China) 纤维蛋白原 抗原:存在情况或阈值:时间点:组织与涂片:序数型:免疫荧光法
Synonyms: Ag Ag IF DFA FGN;凝血因子 I;第一凝血因子;第一因子;纤维朊原;血纤维蛋白原 IFA法;IF法;抗补体免疫荧光法;时间分辨荧光法;荧光原位杂交技术;荧光原位杂交法;荧光抗体 依次型;分类顺序型;定性的;序数型(或称等级型);性质上的;有序型;有序性分类应答;有序性分类结果;秩次型;等级型;筛查;顺序型 凝血功能;凝血功能试验;凝血过程;血液凝固;血液凝固功能;血液凝固过程 存在情况;存在;存在与否;是否存在;阈值;界值;界限;阀值;临界值;存在情况(存在、存在与否、是否存在)或阈值(界值、界限、阀值、临界值) 抗原免疫荧光检测 抗原免疫荧光测定 时刻;随机;随意;瞬间 未作说明的组织;组织;组织 & 涂片 直接免疫荧光分析 直接免疫荧光检测 直接免疫荧光测定 纤维蛋白原 Ag

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=60278-9